Summary: | Obtaining extracts rich in pharmacological components from edible brown seaweeds is essential for their use as functional foods or therapeutic supplements. The present study demonstrated that the cold-water extract of Hizikia fusiformis (HF-C) with a unique composition, unlike hot-water (HF-H) or acid (HF-A) extracts, inhibited NF-κB activation, pro-inflammatory cytokines and glucose transporter expression, and inflammatory glycolysis more than HF-H or HF-A did. Oral administration of HF-C significantly inhibited dextran sodium sulfate-induced colitis in mouse, as evidenced by a decrease in disease activity index and inflammatory cytokine expression, and recovered colonic tissue E-cadherin expression and body weight. Notably, the anti-colitis effect of HF-C was greater than sulfasalazine, an inflammatory bowel disease (IBD) drug. Taken together, the higher anti-inflammatory action of HF-C was due to the different composition of fucoidan compared to the other extracts. Consequently, the results suggest that HF-C may be a therapeutic adjunct to the treatment of IBD.
|